Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 32,290 shares, a decrease of 38.4% from the April 30th total of 52,380 shares. Based on an average daily volume of 13,641 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.1% of the shares of the company are sold short.

Exicure Stock Down 2.3%

XCUR traded down $0.07 during trading on Thursday, reaching $3.04. 2,078 shares of the company’s stock were exchanged, compared to its average volume of 25,323. The company has a market capitalization of $19.36 million, a P/E ratio of -1.96 and a beta of 3.53. The business has a 50 day moving average price of $3.56 and a 200 day moving average price of $4.40. Exicure has a fifty-two week low of $2.63 and a fifty-two week high of $10.80.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Friday, May 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Exicure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Exicure presently has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.